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Abstract
Background: Osteoclasts are the body’s sole bone resorbing cells. Cytokines produced by pro-inflammatory effector T-cells
(TEFF) increase bone resorption by osteoclasts. Prolonged exposure to the TEFF produced cytokines leads to bone erosion
diseases such as osteoporosis and rheumatoid arthritis. The crosstalk between T-cells and osteoclasts has been termed
osteoimmunology. We have previously shown that under non-inflammatory conditions, murine osteoclasts can recruit naı ¨ve
CD8 T-cells and activate these T-cells to induce CD25 and FoxP3 (TcREG). The activation of CD8 T-cells by osteoclasts also
induced the cytokines IL-2, IL-6, IL-10 and IFN-c. Individually, these cytokines can activate or suppress osteoclast resorption.
Principal Findings: To determine the net effect of TcREG on osteoclast activity we used a number of in vitro assays. We found
that TcREG can potently and directly suppress bone resorption by osteoclasts. TcREG could suppress osteoclast differentiation
and resorption by mature osteoclasts, but did not affect their survival. Additionally, we showed that TcREG suppress
cytoskeletal reorganization in mature osteoclasts. Whereas induction of TcREG by osteoclasts is antigen-dependent,
suppression of osteoclasts by TcREG does not require antigen or re-stimulation. We demonstrated that antibody blockade of
IL-6, IL-10 or IFN-c relieved suppression. The suppression did not require direct contact between the TcREG and osteoclasts.
Significance: We have determined that osteoclast-induced TcREG can suppress osteoclast activity, forming a negative
feedback system. As the CD8 T-cells are activated in the absence of inflammatory signals, these observations suggest that
this regulatory loop may play a role in regulating skeletal homeostasis. Our results provide the first documentation of
suppression of osteoclast activity by CD8 regulatory T-cells and thus, extend the purview of osteoimmunology.
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Introduction
The skeletal system is dynamically and constantly remodeled
throughout life to maintain bone integrity. There are multiple
layers of regulation imposed on the skeletal system homeostasis,
including physiological levels of phosphate, calcium, hormones,
mechanical loading (e.g. Wolff’s law) and energy metabolism
(reviewed in [1]). Two cells play a key role in remodeling bone:
osteoclasts and osteoblasts. Osteoclasts are large multinucleated
cells that are the principal, if not sole, bone resorbing cells in the
body. Osteoclasts are derived from the myeloid lineage and
therefore may be considered a specialized immune cell. Balancing
the function of the osteoclasts are osteoblasts, of mesenchymal
origin, which form new bone. Osteoblasts also provide essential
signals for, and regulate the differentiation of, the myeloid lineage
osteoclast precursors by producing macrophage colony-stimulating
factor (M-CSF), receptor activator of NF-kB ligand (RANKL;
Tnfsf11) and other co-stimulatory factors in the bone marrow
[2,3,4,5].
It has been recognized in the last decade that skeletal
homeostasis is dynamically influenced by the immune system.
This emerging field, called osteoimmunology [6], arose from
observations demonstrating that lymphocyte-derived cytokines,
including RANKL, interleukin (IL)-17 and type I and II
interferons, are potent mediators of osteoclast function and
osteoclastogenesis [7,8,9,10,11,12,13]. Osteoclast activity and
numbers are increased by cytokines produced by effector T-cells
leading to bone erosion in inflammatory diseases such as
rheumatoid arthritis and periodontitis. T-cell produced cytokines
also play a critical role in bone cancers, post-menopausal
osteoporosis and in Paget’s disease [14,15,16,17].
The immune system also maintains two counterbalancing cell
types: the effectors (e.g. TH17), which are dominant during the
inflammatory phase, and the regulatory T-cells (TREG). The
transcription factor FoxP3 is a marker of TREG that have the
ability to suppress aberrant activation of self-reactive lymphocytes.
Loss of FoxP3 function results in fatal autoimmune pathology
affecting multiple organs in both humans and mice [18,19,20,21].
Adoptive transfer of T-cells expressing FoxP3 into mice with FoxP3
loss-of-function abolishes the autoimmune pathology [22,23,24,25].
Regulatory T-cells that express FoxP3 also express CD25, the a-
chain of the IL-2 receptor. The transfer of CD4 T-cells depleted of
the CD25
+ fraction (,10%) from a normal adult mouse into a
mouse lacking an intact immune system produces autoimmune
disease [26]. Conversely, transfer of the CD25
+ CD4 T-cells from
normal mice into T-cell–deficient mice suppressed allergy and
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tion [27]. TREG mediate their regulatory function through a
number of mechanisms. First, TREG express anti-inflammatory
cytokines including IL-10, TGFb and IL-35 [28,29,30,31]. Another
mechanism of regulation is by cell-cell contact: cytotoxic T-
lymphocyte antigen-4 (CTLA-4) expressed on TREG binds with
,10 fold higher affinity to co-stimulatory B7 molecules on antigen
presenting cells (APC) than CD28, and thus prevent APC from
activating naı ¨ve T-cells [32]. TREG have also been proposed to
prevent differentiation of effector T-cells by consuming IL-2, IL-4
and IL-7 required for T-cell activation and polarization [33].
Compared to CD4 TREG, the FoxP3
+ CD8 T-cells (referred to
as TcREG here) have not been extensively studied due in part to
their low abundance in lymphoid tissue, and the ability of CD4
TREG to regulate activation of both CD4 and CD8 T-cells
[34,35,36,37]. While a few recent studies have indicated that
TcREG may also regulate the immune system [38,39,40], their
physiological role in immune regulation has not been definitively
established. Other regulatory CD8 T-cells that do not express
FoxP3 have also been observed and studied [41].
Here we examined the interaction between osteoclasts and
TcREG. We uncovered the osteoclast–CD8 T-cell interaction using
a time-series microarray dataset to study osteoclastogenesis. Our
data showed that RANKL treatment of bone marrow monocytes
coordinately induced a number of chemokines and MHC class I
presentation pathway during differentiation [42]. In follow up
experiments, we showed that the osteoclast-secreted chemokines
preferentially recruited CD8 T-cells. Cross-presentation (i.e.
presentation of peptides from extracellular proteins on MHC
class I) of antigens to CD8 T-cells induced IFN-c, IL-6 and IL-2
only in the presence of antigen. Antigen presentation by osteoclasts
has also been subsequently demonstrated for human osteoclasts
derived from peripheral blood mononuclear cells [43]. The
priming of naı ¨ve CD8 T-cells by osteoclasts induced FoxP3,
CD25, CTLA-4, RANKL, and CD122 [44]. The osteoclast-
primed FoxP3
+ CD8 T-cells were able to suppress proliferation of
naı ¨ve responder CD8 T-cells by DCs and thus have a potential
regulatory T-cell activity [44]. Interestingly, the TcREG express
IFN-c and CTLA-4, which inhibit osteoclast activity
[45,46,47,48,49,50], while RANKL increases osteoclast activity.
IL-6 directly inhibits osteoclast activity but can induce RANKL
expression in osteoblasts to increase osteoclast function [14,51].
Thus, these T-cell produced cytokines could potentially activate or
suppress osteoclast activity. We therefore tested if TcREG could
regulate osteoclast resorption activity.
Results
Induction of TcREG by Mature Osteoclasts is Antigen-
dependent
We first show (Fig. 1A) that mature osteoclasts can induce
FoxP3 and CD25 in ovalbumin (OVA)-specific OT-I CD8 T-cells
only in the presence of antigen. The induction of FoxP3 in the
presence of antigen was assayed by both multicolor flow cytometry
(top panels) and by reverse transcription (RT) of RNA isolated
from the co-culture, followed by PCR (middle panel). As controls,
we isolated RNA from purified GFP positive and negative CD4
and CD8 T-cells from the transgenic FoxP3
eGFP reporter mouse
[52,53]. These reporter mice co-express the enhanced green
fluorescent protein (eGFP) and transcription factor FoxP3 under
control of the endogenous promoter. We show that only mature
osteoclasts (incubated in the presence of RANKL for 4 days) have
the ability to induce FoxP3 as the osteoclast precursors (bone
marrow derived monocytes) could not induce the regulatory
phenotype in CD8 T-cells.
TGFb1 can induce regulatory T-cells in the periphery and
in vitro [24,54,55,56]. Avian osteoclasts have been reported to
express the latent form of TGFb [57]. To assess if murine
osteoclasts express TGFb that could induce TcREG, we measured
the expression of TGFb by quantitative real-time PCR (qRT-
PCR). The relative expression (2
DDCt with respect to b-actin) of
TGFb1 in osteoclasts (+M-CSF, +RANKL) over osteoclast
precursors (+MCSF, -RANKL) was determined to be 5.560.8
fold. The relative expression decreased to 0.960.6 fold (about
the same as in the precursors) in the presence of TcREG,
indicating that TcREG suppress TGFb expression by osteoclasts.
However, these results do not address the role of TGFb in
TcREG induction. Furthermore, as bone contains significant levels
of TGFb that is released by the action of osteoclasts
[58,59,60,61], and the effect of TGFb can be dose-dependent,
we added increasing amounts of TGFb to the osteoclast and OT-
I co-cultures to test its effect on the induction of TcREG. While
adding an antibody that neutralizes all three forms of TGFb at
50 mg/ml efficiently blocked the induction of CD4 TREG, the
antibody had no effect, at any dose tested, on the numbers of
TcREG induced (Fig. 1B left). Addition of recombinant murine
TGFb1 also had no statistically significant effect on the induction
of TcREG by osteoclasts at any concentration of TGFb tested
(Fig. 1B right). Taken together these results indicate that while
osteoclasts express TGFb1, the cytokine is not required for
induction of TcREG by osteoclasts; furthermore, in the presence
of TcREG, TGFb1 mRNA levels decreased in osteoclasts.
Consistent with our previous observations [44], the induction of
FoxP3 coincides with production of the cytokines IFN-c, IL-6, IL-
10, again only in the presence of OVA (Fig. 1C top). All of the
cytokines measured by ELISA were found to be expressed by the
CD8 T-cells as measured by intracellular staining and flow
cytometry and not by osteoclasts (Fig. 1C bottom). These results
show that only mature osteoclasts have the ability to induce CD25,
FoxP3 and the cytokines IFN-c, IL-6 and IL-10 in T-cells in an
antigen-dependent manner. Finally, we did not detect any change
in the levels of CD80, MHC class I surface expression, or
detectable levels of MHC class II, on the osteoclasts after 48 hour
of co-culture with CD8 T-cells or TcREG (data not shown).
TcREG Suppress Osteoclast Resorption Activity in vitro
To directly test if osteoclast-induced TcREG affect resorption
activity, we co-cultured purified ovalbumin-specific transgenic
OT-I TcREG with osteoclasts (1:1 ratio). The osteoclasts were
grown on hydroxyapatite-coated slides or wells to measure
resorption activity, rather than bone slices to avoid any
confounding effects of TGFb present in the bone. The data is
presented as the total area resorbed and the number of pits in
the presence of T-cells relative to osteoclast only cultures. The
co-cultures were performed with either ‘‘in-situ’’ produced
TcREG,o rT c REG induced by osteoclasts plated on tissue-culture
plates, then transferred to osteoclasts growing on hydroxyapatite-
coated slides.
Our results (Fig. 2A, B) show that the in situ produced TcREG
suppressed osteoclast resorption activity. We also tested TGFb-
induced OT-II (CD4) TREG (iTREG) in the co-culture assay.
Whereas, in the presence of the induced OT-II TREG osteoclast
resorption activity modestly increased (1.5-fold in area resorbed),
re-stimulation of the TREG with anti-CD3 + anti-CD28 was
required to observe suppression. In contrast, the osteoclast-
induced TcREG could suppress in the absence of re-stimulation.
We also tested if CD8 T-cells when activated by anti-CD3 and
OC-iTcREG Regulate Osteoclast Activity
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osteoclasts. While CD8 T-cells activated in this manner produce
significant levels of IFN-c, they were only able to partially suppress
(,25% suppression) pitting by osteoclasts. Finally, we tested if
in vivo generated TcREG could suppress osteoclast activity. TcREG
were purified from the bone marrow space by cell sorting to
.95% purity, then co-cultured with osteoclasts (at a ratio of 3
osteoclasts to 1 GFP
+ T-cell) on hydroxyapatite-coated plates. The
CD8
+ GFP
+ TcREG population was able to efficiently suppress
osteoclast resorption activity, whereas the CD8
+ GFP
2 population
did not (Fig. 2B).
Our results show that the osteoclast-induced TcREG, whether
produced by co-culture, or isolated from a mouse, have the ability
to suppress osteoclast activity. In experiments shown below, we
address the mechanism by which the TcREG mediate this
suppression of osteoclasts.
TcREG Suppress Osteoclast Differentiation but not
Survival
IFN-c blocks osteoclast differentiation, while RANKL promotes
differentiation and survival of the osteoclasts. As the pitting assays
described above require 7 to 10 days, one mechanism by which
TcREG could mediate a loss of pitting would be to suppress
osteoclast differentiation. To test for the effect of TcREG on
osteoclastogenesis, we cultured bone marrow cells with M-CSF for
three days, and then removed non-adherent cells to enrich for
osteoclast precursors; RANKL was then added with TcREG
(generated on independent wells with mature osteoclasts). After
four days of co-culturing we visualized and enumerated the
osteoclasts using the fluorescent substrate ELF-97 for tartrate
resistant acid phosphatase (TRAP), a marker of osteoclasts [62].
The results show that no TRAP positive cells were induced by
RANKL (top middle panel Fig. 3A) in the presence of TcREG.I n
contrast, many large TRAP positive osteoclasts were observed in
the absence of T-cells (top left), and in the presence of naı ¨ve CD8
Figure 1. Osteoclast-induced TcREG produce IL-10, IL-6, and IFN-c. Mature osteoclasts (day 4) or osteoclast precursors were cultured with no
Ag or OVA protein and then used to prime CD8 T-cells from an OT-I mouse. A. T-cells were collected at 48 h following initiation of co-culture. T-cells
were stained for CD44, CD25 and FoxP3 and then analyzed by flow cytometry. T-cells co-cultured with osteoclasts in the absence of antigen do not
express FoxP3
+ or CD25 (top); FoxP3 and CD25 were induced in the presence of antigen as shown in the representative flow plot. The expression of
FoxP3 was confirmed by reverse-transcription of RNA isolated from the co-culture and subsequent PCR of cDNA. GFP sorted cells from FoxP3
eGFP
reporter mice were used as controls. Only mature (day 4) osteoclasts supported the generation of TcREG (right panel). B. Anti-mouse TGFb was added
to co-cultures at the dose indicated (left). Addition of recombinant murine TGFb1 to co-cultures of CD8 T-cells and osteoclasts at concentration
indicated (right). The percent of input T-cells converted to FoxP3
+ are plotted in both panels. No statistically significant effect was observed on TcREG
induction with either the addition of neutralizing antibody or recombinant TGFb. C. Media was collected and cytokine quantitated by multiplexed
ELISA. After 48 h of co-culture, cells were treated with Golgi stop and PMA plus ionomycin for 6 h. The cells were permeabilized, stained and
evaluated for cytokine production by flow cytometry. While the CD11b
+ osteoclasts were negative for all cytokines, the CD8
+ T-cells stained triple
positive for IL-10, IL-6, and IFN-c. Statistical significance was assessed by non-parametric paired T test: *: P,0.05, **: P,0.01, ***: P,0.001 and
****: P,0.0001.
doi:10.1371/journal.pone.0038199.g001
Figure 2. TcREG inhibit osteoclast resorption. A. Osteoclasts (day 3) lifted and plated on hydroxyapatite-coated plates. OT-I TcREG or OT-II TGFb-
induced FoxP3
+ CD4 T-cells (iTREG) generated in separate dishes were added next day. The co-cultures were re-fed every two days. After seven days,
the wells were treated with bleach, photographed, and total pit area was quantified (results in panel B). Representative images from five replicates
are shown in panel A. No pitting was observed in the presence of TcREG (top right). Larger pits were observed in the presence of iTREG (bottom left),
but TcREG were dominant suppressors (bottom right). B.T c REG suppressed pitting on hydroxyapatite plates without re-stimulation. In contrast, iTREG
could only suppress after re-stimulation (see methods for details). IFN-c producing OT-I T-cells activated by anti-CD3 and anti-CD28 in the presence of
IL-2 could partially suppress pitting by osteoclasts. Activated GFP
+ CD8 T-cells purified by cell sorting from FoxP3
eGFP reporter mice could also
suppress osteoclast pitting, while conventional (GFP
2) CD8 had no affect on pitting. Statistical significance of area resorbed was assessed by
Wilcoxon test: *: P,0.05, **: P,0.01 and ***: P,0.001 relative to osteoclast alone wells.
doi:10.1371/journal.pone.0038199.g002
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TGFb-induced TREG cannot suppress osteoclastogenesis, where as
Zaiss et al. [49] obtained the opposite results. Our results (Fig. 3A)
show that iTREG cannot suppress osteoclastogenesis unless they are
restimulated with anti-CD3 and anti-CD28. To test if IFN-c is
solely responsible for suppression of osteoclast differentiation, we
used bone marrow from IFN-c receptor knockout (IFNcR1
2/2)
mice. We found that TcREG could efficiently suppress osteoclast
differentiation of IFNcR1
2/2 precursors, indicating that addi-
tional cytokines play a role in mediating suppression of
osteoclastogenesis. Finally, we confirmed the suppression using
quantitative real-time PCR of three osteoclast markers (Fig. 3A
bottom right). These marker genes were chosen because they are
expressed in mature osteoclasts and absent in T-cells.
Next, we considered if TcREG could control osteoclast numbers,
and hence function, by regulating their survival or lifespan. For
instance, IFN-c can induce Fas ligand expression in osteoclasts, in
the presence of TNFa to induce apoptosis [63]. In other cell types,
TGFb and IL-18 have been shown to induce Fas ligand [64,65].
As a measure of the effect of TcREG on osteoclast survival, we used
the numbers of TRAP and Annexin-V positive osteoclast after five
days of co-culturing. The results show that TcREG do not decrease
the survival of osteoclasts, as there was a slight increase in the
number of osteoclasts (Fig. 3B left panel), and a slight decrease in
the number of Annexin-V positive osteoclasts (Fig. 3B right panel)
in the presence of TcREG. The results of these experiments indicate
that TcREG suppress the differentiation of the osteoclasts but do
not significantly affect their survival.
TcREG Suppress Mature Osteoclasts by Preventing
Cytoskeletal Reorganization
Osteoclasts must adhere to the bone surface and migrate along
it to resorb [66]; cytoskeletal reorganization is critical for this
process [67,68]. Therefore, we stained for actin rings in osteoclasts
in the presence and absence of TcREG.T c REG were cultured with
mature osteoclasts seeded on bone, or on plastic for 24 h. T-cells
were then removed and the actin rings were visualized using flour-
conjugated phalloidin. In the presence of TcREG, the actin ring
was either eliminated on bone (Fig. 4A and B), or (the actin belt)
was reduced in size on plastic (Fig. 4C).
These results indicate that TcREG can act directly on mature
osteoclasts and prevent the formation of sealing zones. Our data
indicates that TcREG and restimulated iTREG can efficiently block
osteoclastogenesis, but not their survival. As osteoclasts express
MHC class I but not class II [44] it is possible that co-culturing
TcREG in the pitting assay with the osteoclasts re-stimulates the
TcREG but not the iTREG. Therefore, in the next set of
experiments we tested if suppression of osteoclast activity requires
antigen presentation by osteoclasts. We also tested if direct cell
contact between TcREG and osteoclasts is needed to mediate
suppression.
Suppression of Osteoclasts Activity is Mediated by TcREG
Secreted Cytokines
To test if the regulation of osteoclast activity was antigen-
dependent, OT-I FoxP3
+ T-cells were cultured with osteoclasts in
the presence or absence of OVA peptide. As shown in Fig. 5A,
TcREG could suppress osteoclasts to similar levels in the presence
or absence of antigen presentation. Therefore, we next tested if
direct contact between osteoclasts and TcREG was required to
mediate suppression. TcREG were able to suppress osteoclast
activity to a significant level when separated by a membrane with a
0.45 m pore (Fig. 5B). These results indicated that the secreted
cytokines were, to a large extent, responsible for the suppressive
activity.
To identify the specific cytokines responsible for osteoclast
suppression, pre-differentiated TcREG were incubated with mature
osteoclasts in the presence of neutralizing antibodies. Blockade of
IFN-c showed the most significant reduction in osteoclast
inhibition while neutralizing IL-10 and IL-6 also relieved
suppression (Fig. 5C). CTLA-4 blockade showed no effect
confirming that the secreted cytokines IL-6, IL-10, and IFN-c all
contribute to osteoclast suppression. Osteoclasts express FC
receptors (FcR), and there could be a concern about confounding
effects from the added antibody. Although, we used rat anti-mouse
antibodies to minimize the likelihood of mouse FcR from binding
to the rat antibodies, a possibility remains. Second, the active
moiety of some of the cytokines, notably IFN-c is a dimer [69] it is
possible that immune complex formation could confound the
results. To directly address these issues we added duck Hepatitis B
virus (dHBV) polymerase to our co-culture, and titrated mouse-
anti dHBV polymerase antibody (20 to 70 mg/ml). We observed
no effect on suppression (data not shown), indicating that the
antibodies, and potential immune complex formation did not
confound the assay.
To confirm the results of antibody neutralization we generated
osteoclasts from IFNcR1 knockout mice. We found that TcREG
generated from OT-I mice could suppress IFNcR1
2/2osteoclast
pitting to a similar extent as wild-type osteoclasts (Fig. 5D). Taken
together, our data document that TcREG, once generated can
suppress osteoclast resorption directly through secreted cytokines.
Altering the concentration by neutralizing antibody against all
secreted cytokines expressed by TcREG relieved suppression, while
blockade of TcREG expressed CTLA-4 had no measurable effect of
suppression.
Discussion
Many studies have now established that under inflammatory
conditions, T-cell produced cytokines increase osteoclast activity
leading to bone erosion [70,71,72]. This close relationship
between the skeletal and immune systems is illustrated in diseases
such as autoimmune rheumatoid arthritis and periodontitis. The
crosstalk between the immune and skeletal system has been termed
osteoimmunology. Osteoimmunology emerged from the early
pioneering work of Suda and colleagues (reviewed in [72]) and the
demonstration that RANKL, a critical mediator of osteoclasts, is
expressed on T-cells [6]. Here we examined the regulation of
osteoclasts by FoxP3
+ CD8 T-cells (TcREG). Although TcREG have
been documented in humans and mice
[18,22,39,73,74,75,76,77,78,79,80,81,82,83,84,85], they have not
been studied extensively, in part due to their low abundance (0.2 to
2% of CD8 T-cells) in lymphoid organs. In comparison, the well-
studied CD4 regulatory T-cells, TREG, comprise 5–12% of CD4
T-cell in the spleen. The TcREG and the TREG have overlapping
and distinct functions. Both cells express CD25 and the
transcription factor, FoxP3 a marker of the regulatory T-cells
[34,86,87].
Based on the mediator cytokines produced by the TcREG,i n
this work we examined if the osteoclast induce TcREG could
control osteoclast activity. Our results show that the osteoclast-
induced TcREG secreted cytokines (Fig. 1) that could suppress
resorption by osteoclasts (Fig. 2). Induction of TcREG by
osteoclasts required antigen (Fig. 1), through cross presentation
by osteoclasts [44]. Once activated, TcREG, unlike the TREG,d o
not require restimulation to suppress osteoclasts (Fig. 2). To
examine the mechanisms by which suppression is mediated, we
OC-iTcREG Regulate Osteoclast Activity
PLoS ONE | www.plosone.org 5 June 2012 | Volume 7 | Issue 6 | e38199Figure 3. Osteoclast-induced TcREG inhibit osteoclast differentiation, but not survival. A. Osteoclast precursor cells (day 0) were cultured
alone, with pre-differentiated TcREG,i T REG, anti-mouse CD3/CD28 re-stimulated iTREG, or with naı ¨ve T-cells in the presence of GST-RANKL. After four
days, non-adherent cells were removed by aspiration and remaining cells were stained with a fluorescent TRAP substrate ELF-97. Representative
images from four experiments are shown in top panel, and quantitated cells counts are shown below. To test if suppression of osteoclastogenesis
was mediated solely by IFN-c, bone marrow cells from IFNcR1
2/2 mice were used. The results of TRAP staining were confirmed by quantitative real-
time PCR using primers for Acp5 (TRAP), Cathepsin K (CTSK) and matrix metalloprotease-9 (MMP-9). b-actin expression was used for normalization. B.
Osteoclasts, cultured in the absence or presence of TcREG for five days were counted after TRAP staining with ELF-97. To test for increased apoptosis
adherent cells were stained with Annexin V. Each data point is average of three wells per experiment. Statistical significance was assessed by non-
parametric paired T test: *: P,0.05, **: P,0.01 and ***: P,0.001 by comparison to untreated (Untx) osteoclast wells.
doi:10.1371/journal.pone.0038199.g003
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Our data shows that TcREG and iTREG block osteoclastogenesis
(Fig. 3A). The TcREG did not affect the survival of osteoclasts
(Fig. 3B), but TcREG could directly act on mature osteoclasts to
suppress actin ring formation (and actin belt formation; Fig. 4).
To elaborate on the requirement that TcREG do not require
restimulation, we showed that TcREG could suppress osteoclast
activity in the absence of antigen (Fig. 5A) and when separated
from the osteoclasts by a membrane with a 0.45 m pore (Fig. 5B)
indicating the secreted cytokines mediate the suppression. To
indentify the cytokine(s), we used neutralizing antibodies against
the secreted cytokines and found that altering the levels of any of
the three cytokine relieved the suppression of osteoclast activity
(Fig. 5C). Indeed, TcREG could effectively suppress pitting of
IFNcR1
2/2 osteoclasts (Fig. 5D). Although the role of TcREG in
controlling the immune system is still being defined [88], our
results provide a new physiological role for the TcREG: the
inhibition of osteoclast activity under homeostatic conditions.
Regulatory T-cells use a number of mechanisms to suppress the
immune system as noted above, however only a subset of the
mechanisms may be expressed in a given situation. In this context,
we note that the osteoclast-induced TcREG produce IL-6 and IFN-
c, molecules that would normally be considered pro-inflammatory,
but previous studies have shown they can affect osteoclast activity
[89]. Based on a number of recent studies that demonstrate a
remarkable plasticity in TREG responses [90,91], we speculate that
this may be a general phenomenon for regulatory T-cells: the
method of activation and their location may allow them to express
specific effector functions, to regulate cells at hand. This
phenomenon may underlie the apparent multiple types of TREG
observed [34,87].
Summarizing, we demonstrate that FoxP3
+ CD8 T-cells can
suppress osteoclast resorptive function and thus provide a novel
control function for regulatory T-cells beyond regulation of the
immune system. The ability of osteoclasts to induce TcREG and the
ability of TcREG to subsequently regulate osteoclast function
establishes a bi-directional regulatory loop between these two cells
in the bone marrow. Notably, the regulatory loop does not require
the presence, in vitro, of pro-inflammatory cytokines. Indeed, our
ability to isolate functional TcREG from mice, in the absence of any
inflammatory disease (Fig. 2B), indicates that these cells have a role
in maintaining skeletal homeostasis in vivo. In contrast to CD4
TREG, the TcREG may have a more specialized and local function.
The ability of osteoclasts to induce TcREG and their ability to
suppress without restimulation may provide an explanation for the
low levels of TcREG found in vivo: the system is rapidly inducible, so
a large reservoir of TcREG is not needed. The induction of the
TcREG by osteoclasts that suppress osteoclasts would be self-
limiting and lead to small number of TcREG. Osteoclasts remodel
bone as part of basic multicellular unit (BMU) that includes
osteoblasts and other cells [92,93]. The rapid induction of TcREG
also suggests that the local concentration of the TcREG-produced
cytokines is likely to be high, thus requiring a small number of
TcREG. This notion is consistent with our observation that TcREG
suppressed osteoclast slightly less well when separated in a
transwell. Finally, in contrast to CD4 TREG cells, which require
MHC class II for activation, regulatory CD8 T-cells can be
activated by any MHC class I expressing cells. All cells (except red
blood cells) express MHC class I and therefore could activate
TcREG, an abundance of TcREG could suppress host response to
pathogens.
Why does the immune system regulate osteoclasts? We suggest
two possibilities: First, regulatory T-cells have evolved to suppress
the immune system. As osteoclasts are derived from myeloid cells,
they retain the ability to respond to immune signals. Just as
cytokines produced by effector T-cells activate osteoclast activity in
inflammatory bone erosion diseases, the cytokines produced by
TcREG suppress osteoclasts. In addition to ontogeny, a functional
linkage may also exist. The bone marrow is the primary site of
hematopoiesis. Stromal cells line, provide essential support and
form a specialized sealed compartment (‘‘niche’’) for the
hematopoetic stem cells (HSC) [94,95,96,97]. It has been
documented that osteoclast activity modulates the egress of the
hematopoetic precursors (HPC) from the niches [98,99]. We
Figure 4. TcREG suppress mature osteoclasts by effecting the cytoskeletal reorganization: Osteoclasts were cultured either alone or with
TcREG on bovine bone chips for 24 hrs. T-cells were then removed, and osteoclasts were stained with phalloidin-Texas Red to visualize actin rings.
Representative images are shown in panel A. Quantitation of three independent experiments is shown in panel B. Panel C is quantitation of
phalloidin staining of osteoclasts plated on tissue culture treated dishes. Statistical significance of actin ring area was assessed by non-parametric
paired T test: **: P,0.01 in comparison to osteoclast alone.
doi:10.1371/journal.pone.0038199.g004
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activity through production of effector T-cells (TEFF). The TEFF
secreted cytokines increase osteoclast activity during inflammation
to replenish lost immune cells and thus increase circulating
hematopoetic precursors (HPC). To maintain balance or restore
homeostasis after inflammation, TcREG may be used to suppress
osteoclast activity. For example, it is conceivable that the TcREG
evolved to provide an elegant sensor for T-cell lymphopenia. A
Figure 5. TcREG inhibit osteoclast activity in an antigen- and contact-independent manner by secreted cytokines. A. Osteoclasts were
seeded on hydroxyapatite-coated plates and allowed to adhere overnight. The osteoclasts were pulsed with SIINFEKL peptide (+Antigen) or a control
FLAG peptide (-Antigen). OT-I TcREG or naı ¨ve CD8 T-cells were added and co-cultured for 7 days. Cells were re-fed with medium containing M-CSF and
RANKL every 2 to 3 days. The plates were then treated with bleach solution, washed, dried and photographed. Representative photomicrographs are
shown on the left. Quantitation from four experiments of three wells each is shown on the left. B.T c REG were added to top-insert of transwell (0.45-m
membrane) separated from the osteoclast plated on 24-well Corning Osteo-Assay plate. Osteoclast activity was determined by quantifying total pit
area resorbed following 10 days of co-incubation. C. In a culture of both osteoclast and TcREG on Corning Osteo-Assay plates, neutralizing antibodies
against IL-10 (25 mg/ml), IFN-c (50 mg/ml), IL-6 (20 mg/ml) or CTLA-4 (10 mg/ml) were added to determine their impact on osteoclast activity. The cells
were co-cultured for 10 additional days, and re-fed with media containing M-CSF, RANKL every three days. Re-feed media with antibodies were added
on days 3 and 6. D. Pitting assay as described in Panel C were conducted in parallel using osteoclasts from either wild type (WT) or IFNcR1
2/2 mice.
Statistical significance of area resorbed was assessed by non-parametric paired T test: *: P,0.05, **: P,0.01 and ***: P,0.001 in comparison to
osteoclast alone wells.
doi:10.1371/journal.pone.0038199.g005
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resorption, and the subsequent increase in HPC mobilization.
More studies are needed to explore the consequences of this
bidirectional regulation for both the bone and autoimmune
regulation, and to identify the sensors that mediate this regulation.
Materials and Methods
Mice: Five-week-old male C57BL/6 mice were purchased from
Jackson Labs or used from in-house breeding colony.A breeder trio
of FoxP3eGFP reporter mice on a C57BL/6 background were
purchased from Jackson Labs, and bred in-house for these
experiments. OT-I/Rag
2/2 and OT-II/Rag
2/2 mice were
purchased from Taconic. All animals were maintained in the
Department of Comparative Medicine, Saint Louis University
School of Medicine in accordance with institutional and Public
Health Service Guidelines. Saint Louis University School of
Medicine Institutional Animal Care and Use Committee approved
all procedures performed on mice (Protocol 2072). Purchased
animalswereallowedtoacclimateforatleastoneweek,priortouse.
Generation of Osteoclasts
Osteoclast precursors were isolated as previously described
[42,44]. Briefly, the mice were sacrificed by CO2 asphyxiation and
the long bones harvested. The caps of the bones were removed
and bone marrow cells were flushed with 0.05% collagenase
(Worthington) in a-minimum essential medium (aMEM, Invitro-
gen). The cell population was filtered through a 40 m cell strainer,
pelleted, resuspended and maintained in aMEM growth medium
(aMEM supplemented with 10% heat-inactivated fetal bovine
serum [Invitrogen]), penicillin-streptomycin-glutamine (Invitro-
gen) and recombinant murine M-CSF (Peprotech) at 20 ng/ml).
Osteoclasts were generated by addition of recombinant murine
GST-RANKL (gift of Steven Teitelbaum, Washington University
in St. Louis) to a final concentration of 50 ng/ml. M-CSF and
GST-RANKL were added every 48 to 72 h. Cells were harvested
by a 15 m treatment with Versene (Gibco).
Isolation of Splenocytes
Single cell suspensions of spleens were prepared in PBS +1%
FBS by grinding with a sterile syringe plunger and dispersed by
pipetting, then filtering through a 40 m cell strainer. For co-culture
experiments, OT-II CD4 or OT-I CD8 T-cells were prepared by
first enriching for T-cells using Pan-T-cell beads then purified by
negative selection using appropriate magnetic beads (Miltenyi).
The resulting T-cells were routinely .97% pure when stained
with anti-CD3, anti-CD4 and anti-CD8 antibody.
Generation of TcREG
Day 3 osteoclasts cultured in 20 ng/ml M-CSF and 50 ng/ml
GST-RANKL, were seeded at 5610
5 cells/ml/well in the
presence of 5 mM OVA (A-5503; Sigma-Aldrich) in 24-well tissue
culture-treated plates (Corning). After overnight incubation,
medium was removed and (adherent) cells were washed with
pre-warmed (37uC) medium. 2.5610
5 freshly harvested splenic
OT-I transgenic T cells purified by negative selection were added
in 2 mls of complete T-cell media (RPMI, 10% heat-inactivated
FBS (DFBS; HyClone), penicillin-streptomycin-glutamine (Hy-
Clone), non-essential amino acids, sodium pyruvate, HEPES, and
55 mM b-mercaptoethanol. Following 48 h co-culture, T-cell
aliquots were removed and stained intracellularly to assay for
FoxP3 expression. TGFb -induced TREG were generated as
previously described [24]. Briefly, CD4 T-cells were purified from
an OT-II spleen by magnetic beads, and stimulated with plate-
bound anti-CD3 (1 mg/ml) and anti-CD28 (2 mg/ml) in the
presence of IL-2 and rhTGF-b1 (5 ng/ml). After 48 h of
stimulation, the cells were expanded in IL-2 (100 U/ml) contain-
ing media for 48 hours. The iTREG were used directly, or in some
experiments, restimulated with plate bound anti-CD3/anti-CD28
(as above) for an additional 48 hours in the absence of rhTGFb.
Antibodies and Fluorescence Activated Cells Sorting
(FACS)
Anti-mouse antibodies for FACS were: PE-conjugated anti-
mouse CD8a (clone 53-6.7; BD Pharmingen), AF700-conjugated
anti-mouse CD44 (clone IM7; BD Pharmingen), e450-conjugated
anti-mouse FoxP3 (clone FJK-16s, eBioscience), APC-conjugated
anti-mouse IFN-c (XMG1.2, eBioscience), FITC-conjugated anti-
mouse IL-10 (JES5-16E3, eBioscience) and FITC-conjugated
anti-mouse IL-6 (MP5-20F3, eBioscience), and PE-Cy7-conju-
gated anti-mouse CD11b (M1/70, eBioscience). Cells were
blocked with anti-mouse FcgRIII/IIR (BD Pharmingen) for
10 m and then stained for 45 m on ice with fluorophore-
conjugated antibody. Stained cells were pelleted, washed, fixed
with 3% paraformaldehyde and analyzed on LSR instrument
with CellQuest (BD Biosciences) software. FACS data analyses
were performed with FlowJo (Tree Star).
Abs for cytokine neutralization were: anti-mouse IL-10 (clone
JES5-2A5, eBioscience), anti-mouse IFN-c (clone R4-6A2, eBios-
ciences), anti-mouse IL-6 (clone MP5-20F3, eBiosciences), clone
1D11.16 [100] that recognizes all three forms of mammalian
TGFb, and anti-mouse CTLA-4 (clone 63828, R&D Systems).
Cytokine Profiling by Multiplexed ELISA
Cytokine quantitation (IL-6, IL10, and IFN-c) was performed
using multiplexed ELISA (Millipore/Linco Research) per the
vendor’s protocol on a Luminex-100. The data was analyzed using
three-point logistic fitting in Microsoft Excel.
Cytokine Staining
For osteoclast staining, Golgi Stop (BD Biosciences) was added
to T-cell/osteoclast co-cultures at 4 ml/(6610
6) cells and incubated
for 6 h. Osteoclasts were collected using ice-cold PBS and vigorous
pipetting. For T-cell staining, 50 ng/ml phorbol 12-myristate 13-
acetate and 1 mg/ml ionomycin were added to T-cell/osteoclast
cultures for initial 1 h incubation. Golgi Stop (Invitrogen) was then
added, and cultured for 3 h. T-cells were then removed from the
plate using pre-warmed PBS. Cells were pelleted (5 min at 4006g)
and resuspended in PBS plus 1% DFBS. Cells were blocked with
rat anti-mouse FccIII/IIR mAb (BD Biosciences Pharmingen) in
1% DFBS in PBS and stained for 45 min at 4uC with fluorophore-
conjugated Ab, washed, fixed with Fix Buffer (4% Paraformalde-
hyde (Electron Microscopy Sciences), 0.01% Tween-20 (Sigma) in
PBS), washed, permeabilized with Perm Buffer (0.5% BSA
(Sigma), 0.1% Triton-X100 (Sigma) in PBS), washed, stained
overnight at RT, washed and then analyzed using an LSR II
instrument with CellQuest (BD Biosciences) software. Analysis was
performed using FlowJo software (version 8.73; Tree Star).
Differentiation Assay
Freshly harvested osteoclast precursor cells were cultured with
20 ng/ml M-CSF for 3 days on a 15 cm Petri dish (Corning). Cells
were removed with Versene and seeded at 8.5610
4 cells/well on a
96 well plate with M-CSF to allow BM precursor to adhere. The
following day (day 0), GST-RANKL was added to the osteoclast
precursor cell culture in the presence or absence of pre-activated
TcREG. T-cells were washed off (day 5) and the adherent cells were
OC-iTcREG Regulate Osteoclast Activity
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fluorescent substrate, ELF-97 (Invitrogen), in accordance with the
manufacturer’s protocol.
Survival Assay
On day 0, mature osteoclast were plated at 8.5610
4 cells/well
on a 96 well plate alone or with pre-differentiated TcREG. Day 5,
non-adherent cells were removed and remaining cells were
counted and stained with FITC-conjugated Annexin-V (Biotium).
Resorption Assays
For in-situ differentiated TcREG, on day 0, mature osteoclast
(5610
5) were seeded on 24-well hydroxyapatite coated plates
(Corning or BD Biosciences). Day 1, osteoclast were pulsed with
SIINFEKL peptide for 4 h, washed, and then naı ¨ve OT-I T-cells
were added. M-CSF and GST-RANKL were added every 48 h.
Day 10, cells were removed with 10% bleach and pit area was
photographed and quantified using NIH ImageJ.
For pre-differentiated TcREG, day 0, osteoclasts were seeded as
above. Day 1 osteoclasts were pulsed with SIINFEKL peptide or
no antigen for 4 h, washed, and then pre-differentiated TcREG
were added. M-CSF and GST-RANKL were added every 48 h.
On day 7, cells were removed with 10% bleach and pit area was
photographed and quantified using NIH ImageJ.
For transwell assays, osteoclasts were plated as described above.
Cells were allowed to adhere overnight, and media was replaced
with 700 ml of complete T-cell media containing M-CSF and
GST-RANKL in the bottom well. 5610
5 TcREG were added to
top insert in 300 ml. Cells were re-fed every 48 h with M-CSF and
RANKL. Following 10 days of incubation, bottom wells were
treated with bleach to remove cells, and pit area was quantified, as
above.
Purification of TcREG from FoxP3
eGFP Reporter Mice
To purify activated TcREG we activated osteoclasts in vivo by
injecting the FoxP3
eGFP mice with RANKL (1 mg/kg intraperi-
toneally). Two doses of RANKL were given intraperitoneally on
consecutive days; this protocol is modified from [101], where three
doses were administered. The mice were sacrificed 50 hours post
first RANKL dose and bone marrow cells harvested as described
in osteoclast generation section above. Magnetic beads (Miltenyi)
were used to positively select CD8 T-cells. The eluted cells were
stained with V450-conjugated CD3 (clone 17A2; eBioscience) and
PE-conjugated CD8a antibodies and further purified by cell
sorting on Aria instrument with FACS Diva software (BD
Biosciences).
Antibody Neutralization Assay
Immature day two osteoclasts were lifted and 8.5610
4 cells were
seeded on 96-well hydroxyapatite coated plates (Corning). After
overnight incubation, pre-differentiated TcREG (8.5610
4) were
added with neutralizing antibodies. M-CSF and GST-RANKL
were added every 72 h. After additional six days, cells were
removed with 10% hypochlorite, photographed and pit area was
quantified using NIH ImageJ. The lowest concentration of
antibody (see legend Fig. 5C) that gave maximum number of pits
was determined from an antibody titration.
Actin Ring Assay
Mature osteoclast were plated at 3610
3 cell/well on bovine
bone slides or on plastic in a 48 well plate. Following overnight
adherence, TcREG or naı ¨ve OT-I T-cells were added at a 1:1 T-
cell to osteoclast ratio. After a 24 h co-incubation, the non-
adherent cells were removed; adherent cells were fixed (4%
Paraformaldehyde (EMS), 0.2% Triton-X100 (Sigma) in PBS) for
10 minutes, washed thrice with PBS and then stained with
phalloidin-Texas Red (Biotium) for 15 min. The cells were
photographed and actin ring size was quantified using NIH
ImageJ software.
RT-PCR and Quantitative Real-time PCR
Total RNA was purified from cell lysates following manufac-
turers instructions (Agilent technologies). For FoxP3, cDNA was
generated (Invitrogen) and subsequently PCR amplified for 45
cycles. The reaction contained 2.5 mM MgCl2, 0.2 mM dNTPs.
qRT-PCR for CTSK, TRAP and MMP-9 transcripts were
performed on ABI7500 instrument using a one-step (Invitrogen)
SYBR green kit for 40 cycles using input 1 ng total RNA. The
data is expressed as 2
DDCt (relative quantity or RQ) by normalizing
to b-actin expression between samples. The primer sequences used
for analyses of RNA expression span at least one intron, are shown
in Table 1.
Table 1. Primers used for RT-PCR.
Gene Primer sequence Annealing Temperature (6C)
FoxP3 F: 59-CCCACAAGCCAGGCTGATCCC
R: 59-AGAGGCAGGCTGGATAACGGCA
58
CTSK F: 59-GGACCCATCTCTGTGTCCAT
R: 59-CCGAGCCAAGAGAGCATATC
57
TRAP (Acp5) F: 59-TTCCAGGAGACCTTTGAGGA
R: 59-GGTAGTAAGGGCTGGGGAAG
57
MMP-9 F: 59-CATTCGCGTGGATAAGGAGT
R: 59-CACTGCAGGAGGTCGTAGGT
57
TGFb F: 59- GGTGGACCGCAACAACGCCAT
R: 59-TGGGGGTCAGCAGCCGGTTA
58
IDO F: 59-ACTGTGTCCTGGCAAACTGGAAG
R: 59-AAGCTGCGATTTCCACCAATAGAG
58
b-actin F: AAGAGCTATGAGCTGCCTGA
R: TACGGATGTCAACGTCACAC
58
doi:10.1371/journal.pone.0038199.t001
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All statistical analyses were performed with GraphPad Prism
(version 5.0c). Wilcoxon or Student’s T test were used for
determining statistical significance for osteoclast alone and
osteoclast plus treatment as indicated in the Figure legends or in
the methods described above.
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